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Abstract 26 
Background: Gut microbiota composition and function are symbiotically linked with 27 
host health, and altered in metabolic, inflammatory and neurodegenerative disorders. 28 
Three recognized mechanisms exist by which the microbiome influences the gut–brain 29 
axis: modification of autonomic/sensorimotor connections, immune activation, and 30 
neuroendocrine pathway regulation. We hypothesized interactions between circulating 31 
gut-derived microbial metabolites and the blood–brain barrier (BBB) also contribute to 32 
the gut–brain axis. Propionate, produced from dietary substrates by colonic bacteria, 33 
stimulates intestinal gluconeogenesis and is associated with reduced stress 34 
behaviours, but its potential endocrine role has not been addressed.  35 
Results: After demonstrating expression of the propionate receptor FFAR3 on human 36 
brain endothelium, we examined the impact of a physiologically relevant propionate 37 
concentration (1 μM) on BBB properties in vitro. Propionate inhibited pathways 38 
associated with non-specific microbial infections via a CD14-dependent mechanism, 39 
suppressed expression of LRP-1 and protected the BBB from oxidative stress via 40 
NRF2 (NFE2L2) signaling.  41 
Conclusions: Together, these results suggest gut-derived microbial metabolites 42 
interact with the BBB, representing a fourth facet of the gut–brain axis that warrants 43 








The human body plays host to, and exists in symbiosis with, a significant number of 50 
microbial communities, including those of the skin, oral and vaginal mucosae and, most 51 
prominently, the gut [1]. This relationship extends beyond simple commensalism to 52 
represent a major regulatory influence in health and disease, with changes in 53 
abundance of members of the faecal microbiota having been associated with numerous 54 
pathologies, including diabetes, hepatic diseases, inflammatory bowel disease, viral 55 
infections and neurodegenerative disorders [2–8]. Metagenomic studies have revealed 56 
reductions in microbial gene richness and changes in functional capabilities of the faecal 57 
microbiota to be signatures of obesity, liver disease and type II diabetes, and that these 58 
can be modified by dietary interventions [9,10]. The gut microbiome harbours 150 times 59 
more genes than the human genome, significantly increasing the repertoire of functional 60 
genes available to the host and contributing to the harvesting of energy from food [11].  61 
 62 
The primary form of communication within the gut microbe–human super-system is 63 
metabolic, but our understanding of the details of the cross-signalling pathways involved 64 
is limited. It is clear, however, that gut-derived microbial metabolites and products such 65 
as lipopolysaccharide (LPS) can influence human health both in the intestine and 66 
systemically [12,13], with reported effects ranging from mediation of xenobiotic toxicity 67 
[14], through modification of the risk of preterm birth [15] to induction of epigenetic 68 
programming in multiple host tissues [16,17]. A major aspect of microbe–host systems-69 
level communication that is receiving increased attention is the influence the gut 70 





The existence of gut–brain communication is supported by a number of animal and 74 
human studies, although the underlying mechanisms are not always well defined. 75 
Behavioural analysis of antibiotic-treated or germ-free rodents reveals alterations in 76 
both stress responsiveness [19] and anxiety [20–22], although in germ-free models 77 
these findings are complicated by the life-long absence of gut microbes and possible 78 
consequent developmental alterations. Nonetheless, gut-microbe-depleted animals 79 
have been shown to exhibit changes in serotonergic and glutamatergic neuronal 80 
signalling [20] and expression of brain-derived neurotrophic factor (BDNF) within the 81 
limbic system [22,23], providing a molecular correlate for behavioural changes.  82 
 83 
Links between the gut microbiota and brain function have been identified in studies of 84 
humans with autism spectrum disorders (ASD) and attention-deficit hyperactivity 85 
disorder (ADHD). Altered microbial profiles have been identified in children with ASD 86 
[24–26], and oral treatment of autistic children with the non-absorbed, broad-spectrum 87 
antibiotic vancomycin – effectively suppressing the gut microbiota – led to a regression 88 
in autistic behavioural characteristics that was reversed upon antibiotic discontinuation 89 
[27]. Similarly, a small-scale intervention study has suggested not only a link between 90 
lower counts of faecal Bifidobacterium species at six months and increased incidence 91 
of ADHD at 13 years, but also that early probiotic treatment lessens the risk of ADHD 92 
development [28].  93 
 94 
A number of unresolved questions remain as to the mechanism(s) of communication 95 
between the gut microbiota and the brain, but three major pathways have been 96 
proposed: direct modification of vagal or sympathetic sensorimotor function [29], 97 
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inflammatory/immune activity [30] and neuroendocrine crosstalk [31]. While research 98 
in this field has focussed most heavily on direct neural modulation and inflammatory 99 
signalling, the potential role of circulating gut microbe-derived metabolites has been 100 
relatively underexplored. Communication with and across the blood–brain barrier 101 
(BBB), the primary interface between the circulation and the CNS, may therefore 102 
represent a significant mechanism allowing the gut microbiota to influence brain 103 
function. 104 
 105 
There is accumulating evidence that the gut microbiota can affect the integrity of the 106 
BBB, with both broad-spectrum-antibiotic-treated and germ-free mice exhibiting 107 
considerably enhanced barrier permeability and dysregulation of inter-endothelial cell 108 
tight junctions [32,33]. Importantly, these impairments can be reversed upon 109 
conventionalisation. The mechanism(s) by which gut microbes exert their influence 110 
are unclear, but changes to brain chemistry induced by alteration of the gut microbiota 111 
can occur independently of vagal or sympathetic neural pathways and in the absence 112 
of any immune response, strongly suggesting at least a contributory role for soluble 113 
gut-derived microbial metabolites [22]. 114 
 115 
In particular, data highlight a potential role for short-chain fatty acids (SCFAs) as key 116 
microbial mediators in the gut–brain axis. SCFAs are principally produced by the 117 
fermentation of complex plant-based polysaccharides by gut bacteria and are potent 118 
bioactive molecules; stimulating colonic blood flow and upper-gut motility, influencing 119 
H2O and NaCl uptake, providing energy for colonocytes, enhancing satiety and 120 
positively influencing metabolic health in obese and diabetic individuals [34–36]. Of 121 
the SCFAs, acetate is produced in the greatest quantity as a result of fermentation in 122 
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the large intestine, followed by propionate and butyrate [37]. Over 95 % of SCFAs 123 
produced are absorbed within the colon with virtually none appearing in the urine or 124 
faeces [35,38]. However, all three metabolites are detectable in the peripheral blood 125 
of healthy individuals (http://www.hmdb.ca: acetate, 22–42 M; propionate, 0.9–1.2 126 
M; butyrate, 0.3–1.5 M). SCFAs activate members of the free fatty acid receptor 127 
(FFAR) family of G protein coupled receptors; acetate, propionate and butyrate have 128 
affinity in the low millimolar to high micromolar range for FFAR2; propionate and 129 
butyrate have mid to low micromolar affinity for FFAR3 [39].  130 
 131 
The majority of studies looking at the role of SCFAs in the gut–brain axis have focused 132 
on butyrate [40], with relatively few investigating propionate despite its similar plasma 133 
concentration and receptor affinity. Propionate is a highly potent FFAR3 agonist for its 134 
size (agonist activity GTPγS pEC50 (Emax) 3.9-5.7(100%)) and has close to optimal 135 
ligand efficiency (-ΔG=1.26 kcal mol-1 atom-1) for this receptor [41]. While propionate 136 
has been shown to stimulate intestinal gluconeogenesis through direct stimulation of 137 
enteric–CNS pathways [42], and increased intestinal propionate has been associated 138 
with reduced stress behaviours [43] and reward pathway activity [44] in mice and 139 
humans, respectively, its potential role as an endocrine mediator in the gut–brain axis 140 
has not been addressed. Given the presence of FFAR3 on endothelial cells [45], we 141 
hypothesised that propionate targeting of the endothelium of the BBB would represent 142 
an additional facet of the gut–brain axis. We used a systems approach to test this 143 
proposal, performing an unbiased study of the transcriptomic effects of exposure to 144 
physiological levels of propionate upon the BBB, modelled by the immortalised human 145 
cerebromicrovascular endothelial cell line hCMEC/D3, accompanied by in vitro 146 





Microarray analyses 150 
Following initial confirmation of the expression of FFAR3 in human brain endothelium 151 
(Fig. 1a) and on hCMEC/D3 cells (Fig. 1b), we investigated the effect of exposure of 152 
hCMEC/D3 monolayers to 1 μM propionate for 24 h. Such treatment had a significant 153 
(PFDR < 0.1) effect on the expression of 1136 genes: 553 upregulated, 583 154 
downregulated (Fig. 1c). Initially, we used SPIA with all the significantly differentially 155 
expressed genes to identify KEGG signalling pathways inhibited and activated in the 156 
presence of propionate. Protein processing in the endoplasmic reticulum and RNA 157 
transport were activated upon exposure of cells to propionate, which was unsurprising 158 
given gene expression had been induced. A number of pathways associated with non-159 
specific microbial infections (Gram-negative bacteria, viral) were inhibited by 160 
propionate (Fig. 1d), as were the cytosolic DNA-sensing pathway (upregulated by 161 
pathogen DNA during microbial infections, triggering innate immune signalling [46]), 162 
the NFκB signalling pathway and the Toll-like receptor signalling pathway. Of the 163 
19309 genes we examined on the array, 203 of the 224 genes known to be associated 164 
with the BBB were detected (Supplementary Table 1). Eleven of these were 165 
significantly differentially expressed, with the majority being associated with the 166 
inflammatory response. 167 
 168 
Enrichr [47,48] was used to examine KEGG pathways significantly associated with the 169 
list of significantly differentially expressed genes. All 1136 significantly differentially 170 
expressed genes mapped to Enrichr. As with SPIA, the genes were associated with 171 
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KEGG pathways implicated in non-specific microbial infections, and RNA- and 172 
endoplasmic reticulum-associated processes (Fig. 1e).  173 
 174 
WikiPathways analysis (Enrichr) of all the significantly differentially expressed genes 175 
highlighted responses to oxidative stress being associated with propionate treatment 176 
(not shown). Closer examination of the data demonstrated this was linked to NRF2 177 
(NFE2L2) signaling, with the significantly upregulated genes closely associated with 178 
oxidative stress responses (Fig. 1f). 179 
 180 
Pathway validation  181 
Transcriptomic analysis identified two particular clusters of pathways as being 182 
regulated by propionate treatment: those involved in the non-specific inflammatory 183 
response to microbial products (Fig. 1d, e) and those involved in the response to 184 
oxidative stress (Fig. 1f). We, therefore, sought to validate these responses in an in 185 
vitro model of the BBB. 186 
 187 
TLR-specific pathway 188 
Inhibition of the TLR-specific pathway by propionate suggests this metabolite may 189 
have a protective role against exposure of the BBB to bacterial lipopolysaccharide 190 
(LPS), derived from the cell walls of Gram-negative bacteria. In accord with this 191 
hypothesis, exposure of hCMEC/D3 monolayers for 12 h to propionate at physiological 192 
concentrations (1 μM) was able to significantly attenuate the permeabilising effects of 193 
exposure to Escherichia coli O111:B4 LPS (subsequent 12 h stimulation, 50 ng/ml), 194 
measured both through paracellular permeability to a 70 kDa FITC-conjugated dextran 195 
tracer (Fig. 2a) and trans-endothelial electrical resistance (Fig. 2b). To determine the 196 
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specificity of these effects for propionate, we investigated the actions of the closely 197 
related SCFAs acetate and butyrate. While physiologically relevant circulating 198 
concentrations of butyrate (1 µM) replicated the effects of propionate on both trans-199 
endothelial electrical resistance and paracellular tracer permeability, this was not the 200 
case for acetate (65 µM) (Fig. 2a-b).  201 
 202 
Circulating concentrations of propionate are approximately 1 µM at rest, but these may 203 
be expected to increase following consumption of, for example, a meal containing high 204 
levels of fermentable fibre [1], consequently we examined the effects of 10 µM and 205 
100 µM propionate upon the response of hCMEC/D3 monolayers to LPS stimulation. 206 
Both LPS-induced deficits in trans-endothelial electrical resistance (Suppl. Fig. 1a) 207 
and paracellular tracer permeability (Suppl. Fig. 1b) were fully attenuated by higher 208 
doses of propionate, without any obvious further effects beyond those seen with 1 µM 209 
of the SCFA. 210 
 211 
Although hCMEC/D3 cells are a widely used in vitro model of the BBB, they are not 212 
without limitations, particularly in terms of their higher inherent permeability when 213 
compared with other non-human model systems [49]. To ensure the validity of our 214 
findings using hCMEC/D3 cells, we repeated these experiments using primary human 215 
brain microvascular endothelial cells (HBMECs). As with hCMEC/D3 cells, exposure 216 
of HBMEC monolayers for 12 h to propionate (1 μM) significantly attenuated the 217 
permeabilising effects of LPS exposure (subsequent 12 h stimulation, 50 ng/ml), in 218 
terms of both paracellular permeability to a 70 kDa FITC-conjugated dextran tracer 219 
(Suppl Fig. 2a) and trans-endothelial electrical resistance (Suppl Fig. 2b). Given this 220 
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confirmation, subsequent experiments focused solely on the hCMEC/D3 cells as an in 221 
vitro BBB model. 222 
 223 
Paracellular permeability and trans-endothelial electrical resistance are in large part 224 
dependent upon the integrity of inter-endothelial tight junctions [50], which are known 225 
to be disrupted following exposure to LPS [51]. We, therefore, examined the 226 
intracellular distribution of the key tight junction components occludin, claudin-5 and 227 
zona occludens-1 (ZO-1) following treatment with propionate and/or LPS. Exposure of 228 
hCMEC/D3 monolayers to propionate alone (1 μM, 24 h) had no noticeable effect on 229 
the intracellular distribution of any of the studied tight junction components, whereas 230 
treatment with LPS (50 ng/ml, 12 h) caused a marked disruption in the localisation of 231 
all three major tight junction molecules, characterised by a loss of peri-membrane 232 
immunoreactivity (Fig. 2c). Notably, these effects of LPS were substantially protected 233 
against by prior treatment for 12 h with 1 μM propionate.  234 
 235 
LPS initiates a pro-inflammatory response through binding to Toll-like receptor 4, 236 
TLR4, in a complex with the accessory proteins CD14 and LY96 (MD2) [52]; we, 237 
therefore, examined expression of TLR4 signalling components as an explanation for 238 
the protective effects of propionate upon this pathway. While propionate treatment of 239 
hCMEC/D3 cells (1 μM, 24 h) had no significant effect upon expression of mRNA for 240 
TLR4 or LY96 (data not shown), such treatment significantly down-regulated 241 
expression of CD14 mRNA (Fig. 2d), an effect replicated at the level of cell surface 242 
CD14 protein expression (Fig. 2e, f).  243 
 244 
NFE2L2 (NRF2) signalling and protection from oxidative stress 245 
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Enrichr (WikiPathways) analysis indicated that exposure of hCMEC/D3 cells to 246 
propionate resulted in the regulation of a number of antioxidant systems. Of known 247 
human anti-oxidant genes [53], 58 were detected on the array. We had also identified 248 
an additional 6 genes via [54] (Supplementary Table 2). Searches of the genes 249 
associated with each of the individual pathways referenced in Fig. 1f strongly indicated 250 
these changes occurred downstream of the transcription factor nuclear factor, 251 
erythroid 2 like 2 – NFE2L2 (Fig. 3a). Supporting this analysis, exposure of hCMEC/D3 252 
cells for 24 h to 1 µM propionate caused a marked translocation of NFE2L2 from the 253 
cytoplasm to the nucleus (Fig. 3b). Functional analysis of antioxidant pathway activity 254 
was assessed by monitoring reactive oxygen species production in hCMEC/D3 cells 255 
following exposure to the mitochondrial complex I inhibitor rotenone (2.5 μM, 2 h). Pre-256 
exposure of cells to 1 μM propionate for 24 h significantly attenuated the rate of 257 
fluorescent tracer accumulation, indicative of reduced levels of intracellular reactive 258 
oxygen species (Fig. 3c). 259 
 260 
Efflux transporter expression and activity 261 
A key feature of the BBB is the expression of a wide array of efflux transporter proteins, 262 
which limit entry of numerous endogenous and xenobiotic agents to, and promote their 263 
export from, the brain. Amongst these, the proteins P-glycoprotein, BCRP and LRP-1 264 
are prominent examples. We investigated the ability of propionate to both modify 265 
expression of these transporters and, in the case of the ABC transporter proteins P-266 
glycoprotein and BCRP, serve as a direct inhibitor or substrate for the protein. 267 
Exposure of hCMEC/D3 monolayers to propionate at physiological levels (1 μM) for 268 
24 h significantly suppressed expression of LRP-1 without modulating expression of 269 
either BCRP or P-glycoprotein (Supplementary Fig. 1a, b). Similarly, propionate had 270 
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neither a stimulatory nor inhibitory effect upon either BCRP or P-glycoprotein activity, 271 




Considerable effort has gone into interrogating the gut–brain axis over recent years, 276 
with a steadily growing appreciation of the influence of the gut microbiota upon CNS 277 
function in health and disease. Mechanistic studies have identified three principal 278 
aspects to the gut–brain axis: modification of autonomic sensorimotor connections 279 
[29], immune activation [30], and regulation of neuroendocrine pathways [31], all of 280 
which incorporate a role for soluble gut-derived microbial agents, whether metabolic 281 
products or structural microbial components (e.g. LPS) themselves. In the current 282 
study, we identify a fourth facet to the gut–brain axis, namely the interactions between 283 
gut-derived microbial metabolites and the primary defensive structure of the brain, the 284 
BBB. In particular, we identify a beneficial, protective effect of the SCFA propionate 285 
upon the BBB, mitigating against deleterious inflammatory and oxidative stimuli.  286 
 287 
If confirmed in vivo, our findings of protective effects of propionate upon BBB 288 
endothelial cells in vitro will add to the previously described beneficial actions of the 289 
SCFA upon a number of metabolic parameters. Propionate has been shown to 290 
improve glucose tolerance and insulin sensitivity, reduce high-density lipoprotein and 291 
increase serum triglyceride concentrations [35,55,56], all of which result in a more 292 
stable metabolic homeostasis. The effects of propionate upon the BBB that we 293 
describe in this study add to these pro-homeostatic actions, emphasising the 294 
contribution the SCFA plays to maintaining normal physiological function. Given that 295 
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the main source of circulating propionate in humans is the intestinal microbiota [57,58], 296 
following fermentation of non-digestible carbohydrates by select bacterial species 297 
(Fig. 4), propionate thus represents a paradigm of commensal, mutually beneficial 298 
interactions between the host and microbiota. Moreover, consumption of food 299 
containing non-digestible carbohydrates increases circulating propionate 300 
concentrations approximately ten-fold [59,60], suggesting that the anti-inflammatory 301 
effects of the SCFA upon the cerebrovascular endothelium may be another facet of 302 
the known health benefits of high-fibre diets [61]. 303 
 304 
That BBB integrity is influenced by the gut microbiota and that SCFAs may play a role 305 
in this process was recently emphasised in studies of germ-free vs. specific pathogen-306 
free mice, with germ-free animals exhibiting enhanced BBB permeability and disrupted 307 
cerebral endothelial tight junctions [32]. These permeability defects were reversed fully 308 
upon conventionalisation with a pathogen-free microbiota, and partially with 309 
monocultures producing various SCFAs. Moreover, defective BBB integrity could be 310 
ameliorated at least partially by extended oral administration of sodium butyrate. Our 311 
findings thus cement SCFAs as a key group of gut-derived microbial mediators 312 
modulating BBB function, and provide evidence emphasising a direct action through 313 
the circulation. Propionate acts primarily through either of the two free fatty acid 314 
receptors FFAR2 or FFAR3 [41], which although absent from neurones in the CNS 315 
[62] have been identified in the cerebral endothelium [45], with FFAR3 confirmed 316 
herein, indicating a possible mechanism of action. Although further study would be 317 
required to prove it conclusively, our data suggest that FFAR3 may be the predominant 318 
receptor type mediating the protective effects of SCFAs, as while the major ligands for 319 
this receptor, propionate and butyrate, were both able to prevent a functional decline 320 
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in BBB integrity induced by LPS exposure, this was not the case for acetate, an SCFA 321 
with greater potency at FFAR2 [39]. Future work investigating the relative contributions 322 
of the two receptor types to BBB integrity will be informative. 323 
 324 
Notably, and perhaps unsurprisingly, SCFAs cannot fully recapitulate the BBB-325 
restoring effects of conventionalisation of germ-free animals, as revealed in the current 326 
work and previously [32,33]. It, therefore, seems likely that additional circulating gut-327 
derived microbial mediators may contribute to the regulation of BBB function, and are 328 
thus highly deserving of future investigation. Given that upwards of 200 distinct 329 
microbial metabolites have been identified in the circulation of healthy individuals and 330 
animals [61,63], there is clearly great potential for intestinal dysbiosis and the resultant 331 
variation in metabolite levels to influence the BBB. 332 
 333 
This may be highly relevant to the development of neurological disease, as variation 334 
in BBB function is increasingly recognised to impact on cognitive processes, although 335 
the mechanism(s) underlying this link are poorly understood. In particular, defects in 336 
BBB integrity have been linked with impaired memory [64] and linguistic [65] function, 337 
as well as with inferior performance on psychometric tests such as the mini mental 338 
state exam [66] and Oxford handicap scale [67]. Antibiotic-induced intestinal dysbiosis 339 
has been associated with similar cognitive deficits and with a reduction in circulating 340 
gut-derived microbial metabolites [33], but as yet whether the BBB plays a role in this 341 
connection has not been investigated. If this is the case, however, as the current study 342 
suggests, regulation of BBB function by microbe-derived mediators may be an 343 
important component in some of the emerging links between intestinal dysbiosis and 344 
pathologies as significant as depression [68], Parkinson’s disease [69,70] and 345 
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Alzheimer’s disease [71]. Notably, patients with early Parkinson’s or Alzheimer’s 346 
diseases have been shown to bear reduced levels of Bacteroides species within their 347 
faeces [71,72]. Given that Bacteroides spp. are important producers of SCFAs, 348 
including propionate [57], from complex carbohydrates (Fig. 4), this reduction may 349 
lead to a decline in circulating propionate and consequent vulnerability of the BBB, 350 
and, by extension, the brain in these major neurological conditions. 351 
 352 
Modulatory effects of circulating gut-derived microbial metabolites upon the BBB may 353 
also be a component of the beneficial outcomes seen upon consumption of prebiotics 354 
or probiotics in a number of neurological conditions. For example, small-scale clinical 355 
trials have identified beneficial effects of probiotic drinks on cognitive ability in both 356 
Alzheimer’s disease [73] and multiple sclerosis [74], conditions associated with reduced 357 
BBB integrity [75]. Similarly, oral administration of prebiotic oligosaccharides to mice 358 
significantly reduced anxiety and stress behaviours, effects that correlated with 359 
increases in caecal acetate, propionate and butyrate concentrations [43]. Whether such 360 
changes in caecal SCFA reflected plasma levels was not measured, but given that 361 
SCFAs can be transported across the gut epithelium [76,77] increases in circulating 362 
concentrations may be likely. That inflammation contributes to depression has become 363 
clearer over recent years [78], hence it is conceivable that the anti-inflammatory effects 364 
of propionate we describe may underlie at least part of the protective effects of prebiotic 365 
treatment, a proposal which, though speculative, is deserving of further study. 366 
 367 
In summary, we reveal here a significant new aspect of the gut–brain axis, namely the 368 
modulatory effects of circulating gut-derived microbial metabolites upon the 369 
endothelium of the BBB. Given the critical gate-keeping role the BBB plays in 370 
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communication between the periphery and the brain parenchyma, our findings set the 371 
stage for future investigation of the influence the gut microbiota has on this structure, 372 
and the impact intestinal dysbiosis may have upon individual susceptibility to 373 
neurological and psychological diseases. 374 
  375 
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Materials & Methods 376 
Human Tissue  377 
Human post mortem samples were taken from the prefrontal cortex from non-378 
neurologic controls; brains were retrieved from the UK Multiple Sclerosis Society 379 
tissue bank at Imperial College London, under ethical approval from the UK MRC Brain 380 
Bank Network (Ref. No. 08/MRE09/31+5). Brains were selected according to the 381 
following criteria: (i) availability of full clinical history, (ii) no evidence of cancer post 382 
mortem, and (iii) negligible atherosclerosis of cerebral vasculature. Tissue was fixed 383 
in 10% v/v buffered formalin and embedded in paraffin. From each paraffin block, 5 384 
μm sections were cut and used for immunohistochemistry for FFAR3 using standard 385 
protocols [79], with a primary rabbit anti-FFAR3 polyclonal antibody (1:100; Stratech 386 
Scientific, Newmarket, UK), a horseradish peroxidase-conjugated goat anti-rabbit 387 
secondary antibody (1:300; Stratech Scientific, UK), and 2,3-diaminobenzidine and 388 
hydrogen peroxide as chromogens. Images were taken using a Leica DM5000 bright-389 
field microscope equipped with a x40 oil immersion objective, and analysed using NIH 390 
ImageJ 1.51h (National Institutes of Health, USA). 391 
 392 
Cerebromicrovascular cells 393 
The human cerebromicrovascular endothelial cell line hCMEC/D3 was purchased 394 
from VHBio Ltd (Gateshead, UK), maintained and treated as described previously [79–395 
81]. Cells were cultured to confluency in complete EGM-2 endothelial cell growth 396 
medium (Lonza, Basel, Switzerland), whereupon medium was replaced by EGM-2 397 
without VEGF and cells were further cultured for a minimum of 4 days to enable 398 
intercellular tight junction formation prior to experimentation. Primary human 399 
cerebromicrovascular endothelial cells (HBMEC) were purchased from Sciencell 400 
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Research Laboratories (San Diego, CA, USA) and were maintained in ECM growth 401 
medium according to the supplier’s recommendations. Cells were cultured to 402 
confluency in complete ECM (Sciencell Research Laboratories, USA), whereupon 403 
medium was replaced by EGM-2 without VEGF and cells were further cultured for a 404 
minimum of 4 days to enable intercellular tight junction formation prior to 405 
experimentation. For primary cultures, trans-endothelial electrical resistance was 406 
measured as described below, and experiments were only undertaken when this had 407 
reached approximately 200 Ω.cm2. 408 
 409 
Microarrays  410 
hCMEC/D3 cells were grown on 6-well plates coated with calf-skin collagen (Sigma-411 
Aldrich, Gillingham, UK) to confluency as described above, further cultured for 4 days 412 
in EGM-2 medium without VEGF and exposed to propionate (1 μM, 24 h). Cells were 413 
collected into TRIzol (Thermo-Fisher Scientific, UK) and total RNA was extracted using 414 
a TRIzol Plus RNA purification kit (Thermo-Fisher Scientific, UK) and quantified using 415 
an ND-1000 Spectrophotometer (NanoDrop, Wilmington, USA). 416 
 417 
Hybridization experiments were performed by Macrogen Inc. (Seoul, Korea) using 418 
Illumina HumanHT-12 v4.0 Expression BeadChips (Illumina Inc., San Diego, CA). 419 
RNA purity and integrity were evaluated using an ND-1000 Spectrophotometer 420 
(NanoDrop, USA) and an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, 421 
USA). Total RNA was amplified and purified using TargetAmp-Nano Labelling Kit for 422 
Illumina Expression BeadChip (EPICENTRE, Madison, USA) to yield biotinylated 423 
cRNA according to the manufacturer’s instructions. Briefly, 350 ng of total RNA was 424 
reverse-transcribed to cDNA using a T7 oligo(dT) primer. Second-strand cDNA was 425 
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synthesized, in vitro-transcribed, and labelled with biotin-NTP. After purification, the 426 
cDNA was quantified using the ND-1000 Spectrophotometer (NanoDrop, USA). 427 
 428 
Labelled (750 ng) cDNA samples were hybridized to each beadchip for 17 h at 58 °C, 429 
according to the manufacturer's instructions. Detection of array signal was carried out 430 
using Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little 431 
Chalfont, UK) following the bead array manual. Arrays were scanned with an Illumina 432 
bead array reader confocal scanner according to the manufacturer's instructions. The 433 
quality of hybridization and overall chip performance were monitored by visual 434 
inspection of both internal quality control checks and the raw scanned data. Raw data 435 
were extracted using the software provided by the manufacturer (Illumina 436 
GenomeStudio v2011.1, Gene Expression Module v1.9.0). 437 
 438 
Processing and analyses of array data  439 
Raw data supplied by Macrogen were quality-checked, log2-transformed and loess-440 
normalized (2 iterations) using affy [82]. Probes annotated as ‘Bad’ or ‘No match’ in 441 
illuminaHumanv4.db [83] were removed from the dataset (n = 13,631) [84]. After this 442 
filtering step, only probes with valid Entrez identifiers (n = 28,979) were retained for 443 
further analyses. Entrez identifiers were matched to official gene symbols using 444 
‘Homo_sapiens.gene_info’, downloaded from 445 
https://www.ncbi.nlm.nih.gov/guide/genes-expression/ on 14 January 2017. Average 446 
gene expression values were used for identification of differentially expressed genes. 447 





Signaling Pathway Impact Analysis (SPIA) was used to identify Kyoto Encyclopedia of 451 
Genes and Genomes (KEGG) pathways activated or inhibited in hCMEC/D3 cells 452 
exposed to propionate [85]. Enrichr [47,48] was used to confirm KEGG findings (with 453 
respect to pathways, not their activation/inhibition) and to perform Gene Ontology 454 
(GO)- and WikiPathways-based analyses. 455 
 456 
In vitro barrier function assessments  457 
Paracellular permeability and transendothelial electrical resistance were measured on 458 
100 % confluent cultures polarised by growth on 24-well plate polyethylene 459 
terephthalate (PET) transwell inserts (surface area: 0.33 cm2, pore size: 0.4 μm; 460 
Appleton Woods, UK) coated with calf-skin collagen and fibronectin (Sigma-Aldrich, 461 
UK). The permeability of endothelial cell monolayers to 70 kDa FITC-dextran (2 mg/ml) 462 
was measured as described previously [81,86,87]; data are presented as the 463 
contribution to the permeability barrier provided by endothelial cells, Pe, throughout. 464 
Transendothelial electrical resistance (TEER) measurements were performed using a 465 
Millicell ERS-2 Voltohmmeter (Millipore, Watford, UK) and were expressed as Ω.cm2. 466 
In all cases, values obtained from cell-free inserts similarly coated with collagen and 467 
fibronectin were subtracted from the total values. Briefly, cells were treated with 468 
propionate (1 μM) for 24 h prior to analysis of barrier function. In some cases, barrier 469 
integrity was tested by challenge with bacterial lipopolysaccharide (LPS). Confluent 470 
endothelial monolayers were treated with propionate (1 μM) for 12 h, whereupon LPS 471 
(Escherichia coli O111:B4; 50 ng/ml, comparable to circulating levels of LPS in human 472 
endotoxemia [88]) was added for a further 12 h, without wash-out. Barrier function 473 




Efflux transporter assays 476 
Activity of the major efflux transporters P-glycoprotein and BCRP [89] was determined 477 
through the use of commercially available assays (Solvo Biotechnology Inc., 478 
Budapest, Hungary), performed according to the manufacturer’s instructions. Step-479 
wise dose-response curves centred around reported physiological circulating 480 
concentrations of propionate [90] were constructed (n=2) and both activating and 481 
inhibitory effects of propionate upon transporter activity were analysed.  482 
 483 
Flow cytometry analysis 484 
hCMEC/D3 cells were labelled with APC-conjugated mouse monoclonal anti-CD14 485 
(Thermo-Fisher Scientific, Paisley, UK), APC-conjugated mouse monoclonal anti-486 
BCRP (BD Biosciences, Oxford, UK), FITC-conjugated mouse monoclonal LRP1 (BD 487 
Biosciences, UK), PE-conjugated mouse monoclonal anti-MDR1A (BD Biosciences, 488 
UK), unconjugated rabbit polyclonal antibody directed against FFAR3/GPR41 489 
(Flarebio Biotech LLC, College Park, MD, USA) followed by incubation with an AF488-490 
conjugated goat anti-rabbit secondary antibody (Thermo-Fisher Scientific, UK), or 491 
appropriate isotype controls (all BD Biosciences, UK) for analysis by flow cytometry. 492 
Briefly, hCMEC/D3 cells were treated for 24 h with propionate (1 μM), detached using 493 
0.05 % trypsin and incubated with antibodies as described above. 494 
Immunofluorescence was analysed for 20,000 events per treatment using a BD 495 
FACSCanto II (BD Biosciences, UK) flow cytometer and data were analysed using 496 
FlowJo 8.0 software (Treestar Inc., CA, USA).  497 
 498 
Immunofluorescence analysis 499 
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hCMEC/D3 cells were cultured on Lab-Tek™ Permanox™ 8-well chamber slides 500 
coated with calf-skin collagen (Sigma-Aldrich, UK), prior to immunostaining according 501 
to standard protocols [79,81] and using primary antibodies directed against Nrf2 502 
(1:500, Novus Biologicals Ltd., Abingdon, UK), occludin (1:200, Thermo-Fisher 503 
Scientific, UK), claudin-5 (1:200, Thermo-Fisher Scientific, UK) and zona occludens-1 504 
(ZO-1; 1:100, Thermo-Fisher Scientific, UK). Nuclei were counterstained with DAPI 505 
(Sigma-Aldrich, UK). Images were captured using an LSM880 confocal laser scanning 506 
microscope (Carl Zeiss Ltd., Cambridge, UK) fitted with 405 nm, 488 nm, and 561 nm 507 
lasers, and a 63x oil immersion objective lens (NA, 1.4 mm, working distance, 0.17 508 
mm). Images were captured with ZEN imaging software (Carl Zeiss Ltd., UK) and 509 
analysed using ImageJ 1.51h (National Institutes of Health, USA). 510 
 511 
Statistical analyses 512 
Sample sizes were calculated to detect differences of 15 % or more with a power of 513 
0.85 and α set at 5 %, calculations being informed by previously published data 514 
[79,81]. In vitro experimental data are expressed as mean ± SEM, with n=3 515 
independent experiments performed in triplicate for all studies. In all cases, normality 516 
of distribution was established using the Shapiro–Wilkes test, followed by analysis with 517 
two-tailed Student’s t-tests to compare two groups or, for multiple comparison 518 
analysis, 1- or 2-way ANOVA followed by Tukey’s HSD post hoc test. Where data was 519 
not normally distributed, non-parametric analysis was performed using the Wilcoxon 520 
signed rank test. A P value of less than or equal to 5 % was considered significant. 521 
Differentially expressed genes were identified in microarray data using LIMMA [91]; P 522 
values were corrected for multiple testing using the Benjamini–Hochberg procedure 523 
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(False Discovery Rate); a P value of less than or equal to 10 % was considered 524 
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Figure Legends 821 
 822 
Fig. 1: Effects on gene expression of exposure of the hCMEC/D3 cell line to 823 
propionate (1 M, 24 h). (a) Representative images of FFAR3 immunoreactivity within 824 
endothelial cells of capillaries (i) and larger post-capillary (ii) blood vessels in control 825 
human brains post mortem; scale bar 20 μm, sections are 5 μm thick; images are 826 
representative of five independent cases, areas of particular immunoreactivity are 827 
highlighted by black arrowheads. (b) Surface expression of FFAR3/GPR41 by 828 
hCMEC/D3 cells (grey line, unstained cells, black line secondary antibody control, red 829 
line FFAR3), data are representative of three independent experiments. (c) Volcano 830 
plot showing significantly (PFDR < 0.1, red dots) differentially expressed genes. The top 831 
20 up- and down-regulated genes are labelled. (d) SPIA evidence plot for the 1136 832 
significantly differentially expressed genes. Only those human KEGG pathways 833 
associated with non-specific microbial infections are labelled. The pathways at the 834 
right of the red oblique line are significant (P < 0.2) after Bonferroni correction of the 835 
global P values, pG, obtained by combining the pPERT and pNDE using the normal 836 
inversion method. The pathways at the right of the blue oblique line are significant (P 837 
< 0.2) after a FDR correction of the global P values, pG. 04810, Regulation of actin 838 
cytoskeleton (inhibited); 04064, NF-kappa B signaling pathway (inhibited); 04978, 839 
Mineral absorption (inhibited); 03013, RNA transport (activated); 04141, Protein 840 
processing in endoplasmic reticulum (activated); 04350, TGF-beta signaling pathway 841 
(activated); 04623, Cytosolic DNA-sensing pathway (inhibited). (e) Association of all 842 
significantly differentially expressed genes (n = 1136) with KEGG pathways, Enrichr. 843 
(f) Association of all significantly upregulated genes (n = 553) with WikiPathways, 844 
Enrichr. (e, f) The lighter in colour and the longer the bars, the more significant the 845 
35 
 
result is. Significance of data was determined using rank-based ranking; only the top 846 
10 results are shown in each case. 847 
 848 
Fig. 2: Protective effects of propionate against LPS-induced barrier disruption. (a) 849 
Assessment of the paracellular permeability of hCMEC/D3 monolayers to 70 kDa 850 
FITC-dextran following treatment for 24 h with 65 μM acetate, 1 μM butyrate or 1 μM 851 
propionate, with or without inclusion of 50 ng/ml LPS for the last 12 h of incubation; 852 
data are mean ± SEM, n = 3 independent experiments. (b) Trans-endothelial electrical 853 
resistance of hCMEC/D3 monolayers following treatment for 24 h with 65 μM acetate, 854 
1 μM butyrate or 1 μM propionate, with or without inclusion of 50 ng/ml LPS for the 855 
last 12 h of incubation; data are mean ± SEM, n = 3 independent experiments. (c) 856 
Confocal microscopic analysis of expression of the tight junction components claudin-857 
5, occludin and zona occludens-1 (ZO-1) in hCMEC/D3 cells following treatment for 858 
24 h with 1 μM propionate, with or without inclusion of 50 ng/ml LPS for the last 12 h 859 
of incubation. Scale bar (10 μm) applies to all images. Images are representative of at 860 
least three independent experiments. (d) Expression of CD14 mRNA in control and 861 
propionate-treated (1 μM; 24 h) hCMEC/D3 cells according to microarray data (data 862 
are mean ± SEM, n = 3). (e) Surface expression of CD14 protein on control and 863 
propionate-treated hCMEC/D3 cells (grey line, unstained cells, black line secondary 864 
antibody control, red line FFAR3), data are representative of three independent 865 
experiments. (f) Median fluorescence intensity of surface expression of CD14 protein 866 
on control and propionate-treated hCMEC/D3 cells, dashed line indicates isotype 867 




Fig. 3: Protective effects of propionate against oxidative stress. (a) Representation of 870 
stress-response genes significantly upregulated in the current study and directly 871 
influenced by NFE2L2, ‘the master regulator of antioxidant responses’ [54]. (b) 872 
Confocal microscopic analysis of expression of NFE2L2 (Nrf2) in hCMEC/D3 cells 873 
following treatment for 24 h with 1 μM propionate; scale bar (10 μm) applies to all 874 
images. Images are representative of at least three independent experiments. (c) 875 
Production of reactive oxygen species (ROS) in control and propionate pre-treated (1 876 
μM, 24 h) hCMEC/D3 cells treated for 30 min with the mitochondrial complex I inhibitor 877 
rotenone (2.5 μM). Data are mean ± SEM, n=3 independent experiments. 878 
 879 
Fig. 4: Production of propionate by the human gut microbiota. Propionate can be 880 
produced directly or indirectly by cross-feeding from succinate- and lactate-producers 881 
(e.g. Selenomonas, Megasphaera and Veillonella spp.). Image produced using 882 
information taken from [57]. *Akkermansia muciniphila is known to produce 883 
propionate; it is thought to do this via the succinate pathway [57].  884 
 885 
Supplementary Fig. 1: Persistence of the protective effect of propionate upon LPS-886 
induced barrier disruption across different doses. (a) Assessment of the paracellular 887 
permeability of hCMEC/D3 monolayers to 70 kDa FITC-dextran following treatment 888 
for 24 h with 1, 10 or 100 μM propionate, with or without inclusion of 50 ng/ml LPS for 889 
the last 12 h of incubation; data are mean ± SEM, n = 3 independent experiments. (b) 890 
Trans-endothelial electrical resistance of hCMEC/D3 monolayers following treatment 891 
for 24 h with 1, 10 or 100 μM propionate, with or without inclusion of 50 ng/ml LPS for 892 




Supplementary Fig. 2: Protective effects of propionate against LPS-induced barrier 895 
disruption in primary human brain microvascular endothelial cells (HBMEC). (a) 896 
Assessment of the paracellular permeability of HBMEC monolayers to 70 kDa FITC-897 
dextran following treatment for 24 h with 1 μM propionate, with or without inclusion of 898 
50 ng/ml LPS for the last 12 h of incubation; data are mean ± SEM, n = 3 independent 899 
experiments. (b) Trans-endothelial electrical resistance of HBMEC monolayers 900 
following treatment for 24 h with 1 μM propionate, with or without inclusion of 50 ng/ml 901 
LPS for the last 12 h of incubation; data are mean ± SEM, n = 3 independent 902 
experiments. 903 
 904 
Supplementary Fig. 3: Effects of propionate upon expression and activity of typical 905 
cerebromicrovascular efflux transporter systems. (a) Surface expression of BCRP, 906 
LRP-1 and P-glycoprotein on control and propionate-treated (1 μM, 24 h) hCMEC/D3 907 
cells (black, control, red, propionate), data are representative of three independent 908 
experiments. (b) Median fluorescence intensity of surface expression of BCRP, LRP-909 
1 and P-glycoprotein on control and propionate-treated (1 μM, 24 h) hCMEC/D3 cells; 910 
data are mean ± SEM, n=3 independent experiments. (c) Lack of stimulatory effect of 911 
propionate upon BCRP, data are mean ± SEM, n = 4. (d) Lack of inhibitory effect of 912 
propionate upon stimulated ATP-dependent activity of BCRP, data are mean ± SEM, 913 
n = 4. (e) Lack of stimulatory effect of propionate upon P-glycoprotein, data are mean 914 
± SEM, n = 4. (f) Lack of inhibitory effect of propionate upon stimulated ATP-dependent 915 





Supplementary Table 1: Effects of propionate treatment (1 µM, 24 h) upon mRNA 919 
expression of BBB-related genes in hCMEC/D3 cells, grouped in broad functional 920 
categories. Gene names listed in bold were significantly regulated compared to 921 
untreated cells (PFDR < 0.05) 922 
 923 
Supplementary Table 2: Effects of propionate treatment (1 µM, 24 h) upon mRNA 924 
expression of antioxidant system-related genes in hCMEC/D3 cells. Gene names 925 

























































































































































































































































































































































































































































































































































































































































Cell Adhesion/Junctional proteins/Cytoskeletal factors
Symbol Description logFC adj.P.Val
PECAM1 platelet and endothelial cell adhesion molecule 1 -0.518 0.002
CLDN11 claudin 11 0.541 0.024
GJA1 gap junction protein alpha 1 0.434 0.055
CLDN1 claudin 1 0.264 0.062
JAM3 junctional adhesion molecule 3 0.180 0.132
UTRN utrophin -0.155 0.157
CDH2 cadherin 2 0.167 0.184
CLDN7 claudin 7 -0.122 0.270
ANXA1 annexin A1 0.145 0.270
TJP2 tight junction protein 2 -0.124 0.281
CLDN17 claudin 17 -0.124 0.282
CLDN4 claudin 4 0.141 0.341
SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 2
0.118 0.373
CLDN23 claudin 23 -0.108 0.462
JAM2 junctional adhesion molecule 2 -0.110 0.540
TJP1 tight junction protein 1 0.090 0.573
CLDN6 claudin 6 0.092 0.582
LAMA4 laminin subunit alpha 4 -0.078 0.629
LAMA3 laminin subunit alpha 3 -0.070 0.657
DAG1 dystroglycan 1 -0.067 0.663
CLDN20 claudin 20 0.073 0.666
AGRN agrin 0.055 0.694
CLDN12 claudin 12 0.064 0.751
CLDN8 claudin 8 -0.049 0.753
CLDN15 claudin 15 -0.050 0.778
CTNNB1 catenin beta 1 -0.047 0.783
VIM vimentin 0.041 0.792
HAPLN2 hyaluronan and proteoglycan link protein 2 -0.054 0.794
DTNA dystrobrevin alpha 0.053 0.796
ESAM endothelial cell adhesion molecule -0.043 0.799
LAMB2 laminin subunit beta 2 -0.044 0.803
CLDN9 claudin 9 -0.039 0.804
LAMA2 laminin subunit alpha 2 -0.057 0.808
ITM2A integral membrane protein 2A -0.041 0.837
FN1 fibronectin 1 -0.037 0.852
COL4A1 collagen type IV alpha 1 chain 0.030 0.875
TJP3 tight junction protein 3 -0.027 0.894
CLDN3 claudin 3 -0.023 0.906
GJB6 gap junction protein beta 6 0.022 0.911
CDH5 cadherin 5 -0.029 0.920
LAMA1 laminin subunit alpha 1 0.014 0.948
CLDN5 claudin 5 -0.016 0.962
CLDN22 claudin 22 0.013 0.963
ACTB actin beta 0.009 0.965
CLDN10 claudin 10 -0.009 0.966
ADGRA2 adhesion G protein-coupled receptor A2 0.010 0.966
ITGA3 integrin subunit alpha 3 -0.009 0.967
OCLN occludin -0.007 0.969
HSPG2 heparan sulfate proteoglycan 2 0.008 0.973
DMD dystrophin -0.003 0.989
AFDN afadin, adherens junction formation factor 0.003 0.989
MARVELD2 MARVEL domain containing 2 -0.001 0.996
Transporter proteins
Symbol Description logFC adj.P.Val
SLC1A5 solute carrier family 1 member 5 0.400 0.011
SLC44A1 solute carrier family 44 member 1 -0.261 0.030
SLC7A5 solute carrier family 7 member 5 0.206 0.092
TFRC transferrin receptor 0.262 0.099
SLC38A5 solute carrier family 38 member 5 0.194 0.165
SLC38A3 solute carrier family 38 member 3 0.140 0.240
SLC22A5 solute carrier family 22 member 5 0.140 0.272
SLC29A4 solute carrier family 29 member 4 0.144 0.299
SLC22A8 solute carrier family 22 member 8 -0.126 0.308
SLC2A1 solute carrier family 2 member 1 -0.129 0.342
SLC38A2 solute carrier family 38 member 2 0.120 0.381
SLC28A2 solute carrier family 28 member 2 0.133 0.411
SLC5A1 solute carrier family 5 member 1 0.100 0.447
SLC5A6 solute carrier family 5 member 6 0.094 0.452
SLC6A6 solute carrier family 6 member 6 0.096 0.461
SLC1A4 solute carrier family 1 member 4 -0.115 0.462
SLC27A4 solute carrier family 27 member 4 -0.139 0.463
LRP2 LDL receptor related protein 2 0.082 0.501
SLC38A1 solute carrier family 38 member 1 0.091 0.510
SLC22A1 solute carrier family 22 member 1 0.078 0.560
LDLR low density lipoprotein receptor -0.075 0.566
SLC1A3 solute carrier family 1 member 3 0.084 0.581
MFSD2A major facilitator superfamily domain containing 2A 0.079 0.593
ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) 0.066 0.671
INSR insulin receptor 0.060 0.718
AQP4 aquaporin 4 0.060 0.733
SLC16A2 solute carrier family 16 member 2 -0.057 0.780
ABCC5 ATP binding cassette subfamily C member 5 -0.041 0.793
SLCO1C1 solute carrier organic anion transporter family member 1C1 0.041 0.795
SLC29A1 solute carrier family 29 member 1 (Augustine blood group) 0.036 0.807
SLC27A1 solute carrier family 27 member 1 -0.036 0.818
SLC7A3 solute carrier family 7 member 3 0.038 0.824
SLC22A2 solute carrier family 22 member 2 0.035 0.843
SLC16A1 solute carrier family 16 member 1 -0.047 0.847
ABCB1 ATP binding cassette subfamily B member 1 0.029 0.866
AGER advanced glycosylation end-product specific receptor -0.026 0.908
AVPR1A arginine vasopressin receptor 1A -0.023 0.912
ABCA2 ATP binding cassette subfamily A member 2 0.015 0.947
SLC6A9 solute carrier family 6 member 9 0.013 0.949
SLC1A1 solute carrier family 1 member 1 -0.013 0.954
SLC7A1 solute carrier family 7 member 1 0.013 0.955
ABCC1 ATP binding cassette subfamily C member 1 0.012 0.956
SLC22A3 solute carrier family 22 member 3 -0.012 0.957
LEPR leptin receptor -0.009 0.960
SLC16A7 solute carrier family 16 member 7 -0.012 0.962
ABCC4 ATP binding cassette subfamily C member 4 -0.011 0.963
SLC5A3 solute carrier family 5 member 3 -0.009 0.967
SLC7A6 solute carrier family 7 member 6 -0.008 0.969
SLCO2B1 solute carrier organic anion transporter family member 2B1 -0.005 0.983
ABCC2 ATP binding cassette subfamily C member 2 -0.003 0.988
SLCO1B1 solute carrier organic anion transporter family member 1B1 0.003 0.988
SLC2A13 solute carrier family 2 member 13 0.003 0.990
SLC1A2 solute carrier family 1 member 2 0.001 0.995
Inflammatory response
Symbol Description logFC adj.P.Val
TNFSF10 tumor necrosis factor superfamily member 10 -0.684 0.001
PDGFRB platelet derived growth factor receptor beta -0.441 0.015
TNFRSF1A TNF receptor superfamily member 1A -0.289 0.021
TNFRSF12A TNF receptor superfamily member 12A 0.383 0.028
TNFRSF21 TNF receptor superfamily member 21 0.325 0.031
ITGB4 integrin subunit beta 4 -0.205 0.056
TNFAIP6 TNF alpha induced protein 6 0.325 0.118
PODXL podocalyxin like -0.194 0.130
ITGA5 integrin subunit alpha 5 -0.211 0.163
ITGA1 integrin subunit alpha 1 -0.150 0.188
PTGS2 prostaglandin-endoperoxide synthase 2 0.187 0.189
ITGB5 integrin subunit beta 5 -0.156 0.193
CXCL2 C-X-C motif chemokine ligand 2 0.171 0.231
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta -0.139 0.299
SOD1 superoxide dismutase 1, soluble 0.126 0.338
ITGB8 integrin subunit beta 8 -0.144 0.340
NOS1 nitric oxide synthase 1 0.114 0.366
CCR5 C-C motif chemokine receptor 5 (gene/pseudogene) 0.222 0.391
ITGA4 integrin subunit alpha 4 0.161 0.430
CLEC5A C-type lectin domain family 5 member A 0.138 0.441
ITGA6 integrin subunit alpha 6 -0.092 0.442
GRN granulin precursor -0.089 0.455
MMP9 matrix metallopeptidase 9 -0.099 0.475
NR3C1 nuclear receptor subfamily 3 group C member 1 -0.085 0.496
CRH corticotropin releasing hormone -0.092 0.558
AGT angiotensinogen -0.091 0.594
PTGDS prostaglandin D2 synthase -0.097 0.596
NOX4 NADPH oxidase 4 0.070 0.601
MMP2 matrix metallopeptidase 2 -0.088 0.687
SELP selectin P -0.074 0.689
IL1RN interleukin 1 receptor antagonist 0.060 0.692
CXCR3 C-X-C motif chemokine receptor 3 -0.060 0.711
F11R F11 receptor -0.089 0.741
TNFRSF1B TNF receptor superfamily member 1B -0.098 0.760
SEMA7A semaphorin 7A (John Milton Hagen blood group) 0.054 0.770
ITGB3 integrin subunit beta 3 0.049 0.793
ITGAV integrin subunit alpha V -0.033 0.837
TLR2 toll like receptor 2 0.030 0.860
ITGB1 integrin subunit beta 1 0.026 0.880
PTGER3 prostaglandin E receptor 3 -0.022 0.895
TNF tumor necrosis factor -0.016 0.927
ITGB2 integrin subunit beta 2 -0.012 0.951
IL1B interleukin 1 beta -0.033 0.967
CCR2 C-C motif chemokine receptor 2 -0.007 0.970
CD276 CD276 molecule 0.006 0.973
C3 complement C3 -0.001 0.997
Vascular function/coagulation cascade
Symbol Description logFC adj.P.Val
SERPINE2 serpin family E member 2 0.461 0.007
PROCR protein C receptor 0.240 0.046
PLAT plasminogen activator, tissue type -0.242 0.051
SERPINE1 serpin family E member 1 0.244 0.212
PROS1 protein S (alpha) -0.165 0.262
PROC protein C, inactivator of coagulation factors Va and VIIIa -0.128 0.479
CA1 carbonic anhydrase 1 0.081 0.518
VWF von Willebrand factor -0.139 0.567
AVP arginine vasopressin -0.057 0.758
SERPINI1 serpin family I member 1 -0.033 0.840
PLG plasminogen -0.030 0.884
KNG1 kininogen 1 -0.024 0.898
NOS3 nitric oxide synthase 3 0.037 0.905
MYLK myosin light chain kinase -0.014 0.949
PTAFR platelet activating factor receptor -0.013 0.952
EPAS1 endothelial PAS domain protein 1 0.010 0.955
Endothelial proliferation/angiogenesis
Symbol Description logFC adj.P.Val
PDGFB platelet derived growth factor subunit B -0.226 0.090
TMEFF2 transmembrane protein with EGF like and two follistatin like domains 2 0.166 0.170
S100A12 S100 calcium binding protein A12 0.143 0.245
FGF19 fibroblast growth factor 19 -0.157 0.354
IGFBP3 insulin like growth factor binding protein 3 0.091 0.486
RGS5 regulator of G-protein signaling 5 -0.075 0.548
FLT1 fms related tyrosine kinase 1 -0.112 0.572
HNRNPDL heterogeneous nuclear ribonucleoprotein D like -0.084 0.601
VEGFA vascular endothelial growth factor A -0.072 0.617
S100B S100 calcium binding protein B -0.071 0.643
EZH1 enhancer of zeste 1 polycomb repressive complex 2 subunit -0.068 0.722
PTPRB protein tyrosine phosphatase, receptor type B -0.057 0.745
HMGB1 high mobility group box 1 0.044 0.775
PTN pleiotrophin -0.029 0.920
KDR kinase insert domain receptor 0.022 0.934
BTG2 BTG anti-proliferation factor 2 0.012 0.958
EPO erythropoietin -0.011 0.963
Other BBB-related genes
Symbol Description logFC adj.P.Val
EPHA2 EPH receptor A2 -0.249 0.076
MOG myelin oligodendrocyte glycoprotein -0.090 0.546
CLN3 CLN3, battenin -0.085 0.566
SRGN serglycin 0.072 0.574
MBP myelin basic protein -0.066 0.646
RAMP2 receptor activity modifying protein 2 0.054 0.713
CLCN2 chloride voltage-gated channel 2 -0.055 0.733
CPE carboxypeptidase E 0.044 0.811
CYBB cytochrome b-245 beta chain 0.033 0.856
MPZL1 myelin protein zero like 1 0.028 0.864
GAB2 GRB2 associated binding protein 2 -0.030 0.866
MAP3K7 mitogen-activated protein kinase kinase kinase 7 0.028 0.882
APP amyloid beta precursor protein -0.044 0.890
APLP2 amyloid beta precursor like protein 2 0.022 0.914
PLP1 proteolipid protein 1 0.019 0.935
HDC histidine decarboxylase 0.007 0.985
HRH3 histamine receptor H3 0.003 0.989
APOE apolipoprotein E 0.000 1.000
GFAP glial fibrillary acidic protein 0.000 1.000
Supplementary Table 2: Human anti-oxidant genes included in array analyses in this study 
 
Symbol log2 fold change Adjusted P value Synonyms Description 
GCLM† 1.034 1.31210-4 GLCLR glutamate-cysteine ligase modifier subunit 
SRXN1 1.242 1.93410-4 C20orf139, Npn3, SRX, SRX1 sulfiredoxin 1 
TXNRD1* 0.928 2.77010-4 GRIM-12, TR, TR1, TRXR1, TXNR thioredoxin reductase 1 
HMOX1† 0.693 2.77010-4 HMOX1D, HO-1, HSP32, bK286B10 heme oxygenase 1 
FTL† 0.564 2.46710-3 LFTD, NBIA3 ferritin light chain 
SLC7A11† 0.649 3.67610-3 CCBR1, xCT solute carrier family 7 member 11 
TXNL4B 0.388 6.60110-3 DLP, Dim2 thioredoxin like 4B 
NQO1† 0.345 0.015 DHQU, DIA4, DTD, NMOR1, NMORI, QR1 NAD(P)H quinone dehydrogenase 1 
TXNDC9 0.346 0.020 APACD, PHLP3 thioredoxin domain containing 9 
PRDX1* 0.306 0.021 MSP23, NKEF-A, NKEFA, PAG, PAGA, PAGB, PRX1, PRXI, TDPX2 peroxiredoxin 1 
MT1F -0.254 0.039 MT1 metallothionein 1F 
MT1G 0.224 0.043 MT1, MT1K metallothionein 1G 
GLRX3 0.256 0.045 GLRX4, GRX3, GRX4, PICOT, TXNL2, TXNL3 glutaredoxin 3 
TXN* 0.240 0.050 TRDX, TRX, TRX1 thioredoxin 
FTH1† 0.206 0.061 FHC, FTH, FTHL6, HFE5, PIG15, PLIF ferritin heavy chain 1 
GSR* 0.328 0.061 HEL-75, HEL-S-122m glutathione-disulfide reductase 
MSRA -0.222 0.082 PMSR methionine sulfoxide reductase A 
TXNDC5 0.217 0.085 ENDOPDI, ERP46, HCC-2, HCC2, PDIA15, STRF8, UNQ364 thioredoxin domain containing 5 
MT1M -0.213 0.106 MT-1M, MT-IM, MT1, MT1K metallothionein 1M 
GPX7 0.210 0.110 CL683, GPX6, GPx-7, GSHPx-7, NPGPx glutathione peroxidase 7 
TXNRD2 -0.166 0.164 SELZ, TR, TR-BETA, TR3, TRXR2 thioredoxin reductase 2 
ERP44 0.170 0.165 PDIA10, TXNDC4 endoplasmic reticulum protein 44 
PRDX4 0.153 0.173 AOE37-2, AOE372, HEL-S-97n, PRX-4 peroxiredoxin 4 
SOD2 0.191 0.238 IPO-B, IPOB, MNSOD, MVCD6, Mn-SOD superoxide dismutase 2, mitochondrial 
PDIA6 0.132 0.250 ERP5, P5, TXNDC7 protein disulfide isomerase family A member 6 
TXNDC8 -0.176 0.262 SPTRX-3, TRX6, bA427L11.2 thioredoxin domain containing 8 
GPX4 -0.125 0.315 GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx, snPHGPx glutathione peroxidase 4 
SOD1 0.126 0.338 ALS, ALS1, HEL-S-44, IPOA, SOD, hSod1, homodimer superoxide dismutase 1, soluble 
Symbol log2 fold change Adjusted P value Synonyms Description 
TMX1 0.140 0.354 PDIA11, TMX, TXNDC, TXNDC1 thioredoxin related transmembrane protein 1 
GLRX -0.110 0.375 GRX, GRX1 glutaredoxin 
TXNDC17 0.111 0.404 TRP14, TXNL5 thioredoxin domain containing 17 
MT1A -0.096 0.479 MT1, MT1S, MTC metallothionein 1A 
PRDX3 0.084 0.486 AOP-1, AOP1, HBC189, MER5, PRO1748, SP-22, prx-III peroxiredoxin 3 
GLRX2 0.086 0.500 CGI-133, GRX2 glutaredoxin 2 
NME9 0.093 0.506 NM23-H9, TXL-2, TXL2, TXNDC6 NME/NM23 family member 9 
TXNDC12 0.114 0.539 AG1, AGR1, ERP16, ERP18, ERP19, PDIA16, TLP19, hAG-1, hTLP19 thioredoxin domain containing 12 
MT1X 0.104 0.544 MT-1l, MT1 metallothionein 1X 
PRDX6 0.081 0.549 1-Cys, AOP2, HEL-S-128m, NSGPx, PRX, aiPLA2, p29 peroxiredoxin 6 
GPX6 -0.087 0.567 GPX5p, GPXP3, GPx-6, GSHPx-6, dJ1186N24, dJ1186N24.1 glutathione peroxidase 6 
GPX3 -0.073 0.622 GPx-P, GSHPx-3, GSHPx-P glutathione peroxidase 3 
TMX2 0.063 0.637 CGI-31, PDIA12, PIG26, TXNDC14 thioredoxin related transmembrane protein 2 
CAT 0.068 0.642 - catalase 
PRDX5 -0.064 0.662 ACR1, AOEB166, B166, HEL-S-55, PLP, PMP20, PRDX6, PRXV, SBBI10, prx-V peroxiredoxin 5 
MT1E -0.091 0.687 MT-1E, MT-IE, MT1, MTD metallothionein 1E 
GPX5 0.053 0.694 HEL-S-75p glutathione peroxidase 5 
GPX1 -0.059 0.698 GPXD, GSHPX1 glutathione peroxidase 1 
SOD3 -0.048 0.763 EC-SOD superoxide dismutase 3, extracellular 
GLRX5 -0.047 0.777 C14orf87, FLB4739, GRX5, PR01238, PRO1238, PRSA, SIDBA3, SPAHGC glutaredoxin 5 
SELENOP 0.040 0.794 SELP, SEPP, SEPP1, SeP selenoprotein P 
TXN2 0.052 0.832 COXPD29, MT-TRX, MTRX, TRX2 thioredoxin 2 
CCS -0.031 0.841 - copper chaperone for superoxide dismutase 
MT1H 0.041 0.853 MT-0, MT-1H, MT-IH, MT1 metallothionein 1H 
CP 0.023 0.889 CP-2 ceruloplasmin 
TXNIP 0.151 0.899 ARRDC6, EST01027, HHCPA78, THIF, VDUP1 thioredoxin interacting protein 
TXNDC11 -0.021 0.907 EFP1 thioredoxin domain containing 11 
PRDX2 0.016 0.935 HEL-S-2a, NKEF-B, NKEFB, PRP, PRX2, PRXII, PTX1, TDPX1, TPX1, TSA peroxiredoxin 2 
MT2A -0.014 0.942 MT2 metallothionein 2A 
NME8 -0.015 0.943 CILD6, HEL-S-99, NM23-H8, SPTRX2, TXNDC3, sptrx-2 NME/NM23 family member 8 
TXNDC2 -0.012 0.953 SPTRX, SPTRX1 thioredoxin domain containing 2 
Symbol log2 fold change Adjusted P value Synonyms Description 
TMX4 -0.011 0.961 DJ971N18.2, PDIA14, TXNDC13 thioredoxin related transmembrane protein 4 
MT1B -0.009 0.963 MT-1B, MT-IB, MT1, MT1Q, MTP metallothionein 1B 
TXNL1 -0.013 0.968 HEL-S-114, TRP32, TXL-1, TXNL, Txl thioredoxin like 1 
GPX2 -0.008 0.969 GI-GPx, GPRP, GPRP-2, GPx-2, GPx-GI, GSHPX-GI, GSHPx-2 glutathione peroxidase 2 
TMX3 -0.007 0.982 PDIA13, TXNDC10 thioredoxin related transmembrane protein 3 
 
†Anti-oxidant genes identified from Enrichr search and Gorrini et al. (2013), and included in Fig. 3a. 
*Anti-oxidant genes identified from Enrichr search, Gorrini et al. (2013) and Gelain et al. (2009), and included in Fig. 3a. 
